We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

TC BioPharm Initiates Phase I Trial of Allogeneic Gamma Delta T Cell Therapy in Acute Myeloid Leukemia Patients

Product News   Apr 26, 2019

 
TC BioPharm Initiates Phase I Trial of Allogeneic Gamma Delta T Cell Therapy in Acute Myeloid Leukemia Patients

The ÚHKT and TCB clinical teams pictured in the Prague trial center.

FURTHER INFORMATION
 
 
 

Related Product News

Adaptate Biotherapeutics Formed To Develop T-cell Modulating Antibody-based Therapies

Product News

A new company aims to modulate γd T-cell activity using therapeutic antibodies, with the potential to trigger an immune response against cancer.

READ MORE

Live-Cell Analysis Handbook

Product News

Sartorius has announced the publication of the third edition of its Live-Cell Analysis Handbook.

READ MORE

Tumor Regression with New Antibody-Drug Conjugate

Product News

Iksuda Therapeutics (Iksuda), a developer of next generation Antibody Drug Conjugates (ADCs), has announced the first data on its lead ADC, IKS01.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE